Heron Therapeutics Inc vs The Coca-Cola Co K — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while The Coca-Cola Co K trades at $82.1 (market cap $353.32B). The key difference: The Coca-Cola Co K is far larger — about 3863.1× Heron Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | KO | |
|---|---|---|
Market Cap | $91.46M | $353.32B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $84.92 |
52-Week Low | $0.39 | $65.67 |
Enterprise Value | $189.36M | $383.39B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.58% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Coca-Cola (KO) trades at $82.08, up 0.64% on the day, with a bullish analyst consensus and strong earnings beats in recent quarters. The stock shows robust profitability with a 27.8% net margin and 45.8% ROE, though valuations like a P/E of 25.82 are elevated. Technicals are mixed with a bearish overall signal but support near $82. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
Outlook remains positive given consistent dividend growth, earnings outperformance, and a $90.67 price target. Risks include high debt levels and regional demand volatility. The stock offers stability for income investors but faces valuation pressures amid macroeconomic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →